Business Wire

The 200-MW project caps Alliant Energy’s historic solar buildout to benefit customers and communities

MADISON, Wis.--(BUSINESS WIRE)-- Alliant Energy announced it successfully completed constructing its Grant County Solar Project. The 200-megawatt (MW) solar array in Potosi, Wisconsin, can generate enough electricity to power more than 50,000 homes annually.

The project’s completion is the culmination of Alliant Energy’s multi-phase buildout of 12... (continue reading...)

AI workflow enhances precision of progression-free survival estimates in metastatic breast cancer, enabling more effective and personalized treatments

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- nference, a company dedicated to transforming healthcare by making biomedical data computable, will present research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The poster, titled A deep learning-enabled workflow to... (continue reading...)

U.S. Focused Fund to Invest Opportunistically Across Asset Classes

NEW YORK--(BUSINESS WIRE)-- Town Lane (“Town Lane” or the “Firm”), an opportunistic real estate investment firm, completed yesterday the final close of its inaugural fund, Town Lane Real Estate Opportunities Fund I (“Fund I”), with $1.25B in total commitments. The fund was oversubscribed and closed on its investor commitments in the first half of 2024 above its initial $1.0 billion... (continue reading...)

RESTON, Va.--(BUSINESS WIRE)-- Science Applications International Corp. (Nasdaq: SAIC) announced today that the company’s board of directors declared a cash dividend of $0.37 per share of the company’s common stock payable on July 26, 2024 to stockholders of record on July 12, 2024.

SAIC intends to continue paying dividends on a quarterly basis, although the declaration of any future dividends will be determined by the board of directors each quarter and will... (continue reading...)

– Simultaneously Published by the Journal of Clinical Oncology –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in the Journal of Clinical Oncology. The company... (continue reading...)